NASDAQ:CDXS - Codexis Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.20
  • Forecasted Upside: 236.28 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$10.17
▼ -0.58 (-5.40%)

This chart shows the closing price for CDXS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Codexis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CDXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CDXS

Analyst Price Target is $34.20
▲ +236.28% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Codexis in the last 3 months. The average price target is $34.20, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 236.28% upside from the last price of $10.17.

This chart shows the closing price for CDXS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Codexis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/22/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/20/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/18/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/2/2022CowenInitiated CoverageBuy$39.00Low
2/25/2022HC WainwrightReiterated RatingBuy$38.00High
11/5/2021HC WainwrightBoost Price TargetBuy$33.00 ➝ $38.00High
10/15/2021HC WainwrightBoost Price TargetBuy$28.00 ➝ $33.00Low
10/14/2021CowenBoost Price TargetOutperform$25.00 ➝ $32.00Low
10/1/2021Craig HallumReiterated RatingBuy$30.00Low
8/6/2021HC WainwrightBoost Price TargetBuy$27.00 ➝ $28.00Medium
8/6/2021Piper SandlerBoost Price TargetOverweight$32.00 ➝ $34.00High
6/18/2021Stifel NicolausReiterated RatingBuy$30.00High
6/18/2021HC WainwrightBoost Price TargetBuy$27.00High
4/12/2021Piper SandlerInitiated CoverageOverweight$32.00High
3/1/2021Stifel NicolausInitiated CoverageBuy$30.00Low
2/26/2021HC WainwrightBoost Price TargetBuy$21.00 ➝ $26.00High
12/30/2020BenchmarkBoost Price TargetBuy$21.00 ➝ $29.00N/A
8/7/2020HC WainwrightReiterated RatingBuy$21.00High
7/15/2020StephensInitiated CoverageOverweight$16.00High
5/11/2020HC WainwrightLower Price TargetBuy$22.50 ➝ $21.00High
3/10/2020BenchmarkInitiated CoverageBuyHigh
2/28/2020HC WainwrightReiterated RatingBuy$22.50High
12/24/2019HC WainwrightReiterated RatingBuy$22.50High
8/8/2019HC WainwrightReiterated RatingBuy$22.50Medium
3/4/2019HC WainwrightBoost Price TargetBuy$22.50High
2/27/2019Craig HallumBoost Price TargetBuy$20.00 ➝ $25.00Medium
1/17/2019First AnalysisUpgradeNeutral ➝ Outperform$12.00 ➝ $19.00High
1/15/2019Jefferies Financial GroupBoost Price TargetBuy$4.00 ➝ $20.00Medium
1/14/2019HC WainwrightReiterated RatingBuy$16.50High
12/10/2018StephensBoost Price TargetOverweight$16.00 ➝ $25.00Medium
11/12/2018HC WainwrightSet Price TargetBuy$17.00High
9/5/2018Craig HallumBoost Price TargetBuy$15.00 ➝ $20.00Medium
6/19/2018CowenInitiated CoverageOutperform$18.00Medium
5/16/2018StephensInitiated CoverageOverweight$16.00High
3/12/2018HC WainwrightSet Price TargetBuy$12.00High
11/21/2017HC WainwrightReiterated RatingBuy$8.50N/A
10/13/2017Jefferies Financial GroupBoost Price TargetBuy$9.00 ➝ $11.00N/A
10/13/2017HC WainwrightBoost Price TargetBuy ➝ Buy$8.00 ➝ $8.50N/A
10/2/2017Jefferies Financial GroupReiterated RatingBuy$8.00 ➝ $9.00Low
8/11/2017HC WainwrightSet Price TargetBuy$8.00High
5/31/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$8.00High
(Data available from 5/19/2017 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/21/2021
  • 3 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
11/20/2021
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/20/2021
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/19/2022
  • 1 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/18/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/20/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2022
  • 2 very positive mentions
  • 23 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
5/19/2022

Current Sentiment

  • 2 very positive mentions
  • 23 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Codexis logo
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $10.17
Low: $9.96
High: $10.87

50 Day Range

MA: $16.59
Low: $9.70
High: $21.89

52 Week Range

Now: $10.17
Low: $9.47
High: $42.01

Volume

559,018 shs

Average Volume

1,103,503 shs

Market Capitalization

$664.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Codexis?

The following Wall Street research analysts have issued reports on Codexis in the last year: Cowen Inc, Craig Hallum, HC Wainwright, Piper Sandler, Stifel Nicolaus, StockNews.com, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for CDXS.

What is the current price target for Codexis?

0 Wall Street analysts have set twelve-month price targets for Codexis in the last year. Their average twelve-month price target is $34.20, suggesting a possible upside of 236.3%.
View the latest price targets for CDXS.

What is the current consensus analyst rating for Codexis?

Codexis currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CDXS will outperform the market and that investors should add to their positions of Codexis.
View the latest ratings for CDXS.

How do I contact Codexis' investor relations team?

Codexis' physical mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company's listed phone number is (650) 421-8100 and its investor relations email address is [email protected] The official website for Codexis is www.codexis.com. Learn More about contacing Codexis investor relations.